Evidence map›Paper›PMID 32883248›Full record

Observational studyBMC public health2020

Strategies for increasing impact, engagement, and accessibility in HIV prevention programs: suggestions from women in urban high HIV burden counties in the Eastern United States (HPTN 064).

Jasmine A Abrams, Michelle Odlum, Emily Tillett, Danielle Haley, Jessica Justman, Sally Hodder, Linda Vo, Ann O'Leary, Paula M Frew, HIV Prevention Trials Network 064 (HTPN) Study Team

Registry-linked trialAbstract readObservational Study
In one paragraph

Observational study in BMC public health, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00995176 (The Women's HIV SeroIncidence Study), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00995176 completednot on this map

The Women's HIV SeroIncidence Study (ISIS)

TypeobservationalSponsorHIV Prevention Trials NetworkRan2009 to 2011Enrolled2,099ConditionsHIV Infections
3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jasmine A AbramsDepartment of Community Health Sciences, Boston University School of Public Health, 801 Massachusetts Avenue (Crosstown Center), Rm 434, Boston, MA, 02118, USA. abramsja@bu.edu.ORCID http://orcid.org/0000-0002-1464-9156
Michelle OdlumColumbia University School of Nursing, New York, NY, USA.
Emily TillettDepartment of Psychology, University of Maryland, Baltimore County, Baltimore, MD, USA.
Danielle HaleyDepartment of Community Health Sciences, Boston University School of Public Health, 801 Massachusetts Avenue (Crosstown Center), Rm 434, Boston, MA, 02118, USA.
Jessica JustmanMailman School of Public Health, Columbia University, New York, NY, USA.
Sally HodderWest Virginia Clinical and Translational Science Institute, West Virginia University, Morgantown, WV, USA.
Linda VoDepartment of Medicine, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA, USA.
Ann O'LearyDivision of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Paula M FrewSchool of Public Health, University of Nevada, Las Vegas, NV, USA.
HIV Prevention Trials Network 064 (HTPN) Study Team

Funding

LOC: HIV Prevention Trials NetworkUM1AI068619 · NIAID · FAMILY HEALTH INTERNATIONAL · PI MYRON Scott COHEN, Sinead Delany-Moretlwe · 2011 to 2026
$779.5M
SDMC: HPTN 084 Pregnancy SupplementUM1AI068617 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Elizabeth Renata Brown, Deborah J Donnell · 2011 to 2026
$204.9M
LC: HIV Prevention Trials Network - Laboratory Support for the SARS-CoV-2 Seroprevalence Study (CoVPN 5002)UM1AI068613 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SUSAN H ESHLEMAN, Mark A Marzinke · 2011 to 2026
$100.2M
West Virginia IDEA-CTRU54GM104942 · NIGMS · WEST VIRGINIA UNIVERSITY · PI Sally Lynn Hodder · 2012 to 2026
$81.0M
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
Institute for Clinical and Translational Research (UL1)UL1RR025005 · NCRR · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2007 to 2011
$75.8M
Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Carlos del Rio · 2002 to 2026
$74.0M
University of North Carolina Global HIV Prevention and Treatment Clinical Trials Unit 2024 SupplementUM1AI069423 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, MINA CHRISTINE HOSSEINIPOUR · 2012 to 2026
$71.8M
Columbia Partnership for Prevention and Control of HIV/AIDS Clinical Trials UnitUM1AI069470 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MAGDALENA ELZBIETA SOBIESZCZYK · 2012 to 2026
$44.8M
UNC CLINICAL AND TRANSLATIONAL SCIENCE AWARD: BPCAUL1RR025747 · NCRR · UNIV OF NORTH CAROLINA CHAPEL HILL · PI RUNGE, MARSCHALL S. · 2008 to 2011
$44.6M
Terry Beirn CPCRA Clinical Trials UnitUM1AI069503 · NIAID · GEORGE WASHINGTON UNIVERSITY · PI KAN, VIRGINIA · 2012 to 2020
$38.5M
The Johns Hopkins Baltimore-Washington-India Clinical Trials Unit (BWI CTU)UM1AI069465 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Charles W. Flexner, Amita Gupta · 2012 to 2026
$34.1M
Center for AIDS Research, University of North Carolina at Chapel Hill AI050410Centers for Innovative Research to Control AIDS, Mailman School of Public Health, Columbia University 5U1Al069466Emory University (EU) HIV/AIDS Clinical Trials Unit 5UO1AI069418NCRR NIH HHS UL1 RR025005NCRR NIH HHS UL1 RR025008NCRR NIH HHS UL1 RR025747NIAID NIH HHS P30 AI050409NIAID NIH HHS P30 AI050410NIAID NIH HHS U01 AI069418NIAID NIH HHS U01 AI069423NIAID NIH HHS U01 AI069465NIAID NIH HHS UM1 AI068613NIAID NIH HHS UM1 AI068619NIAID NIH HHS UM1 AI069423NIAID NIH HHS UM1 AI069465NIAID NIH HHS UM1 AI069470NIAID NIH HHS UM1 AI069503NIDA NIH HHS 7K01DA046307NIDA NIH HHS K01 DA046307NIDA NIH HHS L30 DA046839NIDA NIH HHS UM 1AI068617NIGMS NIH HHS U54 GM104942NIMH NIH HHS UM1AI068613North Carolina Translational and Clinical Sciences Institute, University of North Carolina at Chapel Hill RR 025747The Johns Hopkins Adult AIDS Clinical Trial Unit AI069465The Johns Hopkins Clinical and Translational Science Award UL1 RR 25005The Terry Beirn Community Programs for Clinical Research on AIDS Clinical Trials Unit 5 UM1 AI069503-07University of North Carolina Clinical Trials Unit AI069423
6 · The paper itself

Abstract

backgroundMerely having the tools to end HIV is insufficient. Effectively ending the epidemic necessitates addressing barriers that impede engagement in biomedical and behavioral prevention and wide scale implementation and utilization of existing interventions. This qualitative study identifies suggestions for increasing access to, engagement in, and impact of HIV prevention among women living in cities in high HIV burden counties in the eastern US.

methodsData analyzed for the current study were collected via a qualitative sub-study within the HIV Prevention Trials Network Study 064 (HPTN 064), a multisite observational cohort study designed to estimate HIV incidence among women residing in communities with elevated HIV prevalence who also reported personal or partner characteristics associated with increased risk of HIV acquisition. Focus group and interview participants in the qualitative sub-study (N = 288) were from four cities in the eastern US.

resultsThematic analyses revealed four themes describing women's most frequently stated ideas for improving prevention efforts: 1) Promote Multilevel Empowerment, 2) Create Engaging Program Content, 3) Build "Market Demand", and 4) Ensure Accessibility. We conducted additional analyses to identify contradictory patterns in the data, which revealed an additional three themes: 1) Address Structural Risk Factors, 2) Increase Engagement via Pleasure Promotion, 3) Expand Awareness of and Access to Prevention Resources.

conclusionsFindings may be useful for enhancing women's engagement in and uptake of behavioral and biomedical HIV prevention resources, improving policy, and addressing multilevel risk factors.

trial registrationClinicaltrials.gov: NCT00995176 , prospectively registered.

Indexed as

HIV InfectionsFemaleFocus GroupsHumansIncidenceQualitative ResearchRisk FactorsUnited StatesBiobehavioral interventionHIV hotspotsImplementation sciencePrEPSexual health

Identifiers

PMID32883248
PMCPMC7469400

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.